ESMO 2023 movers – who won and who lost?
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.